Mucora Therapeutics

Mucora Therapeutics is a biotechnology company developing a novel class of site-specific immunotherapies called muco-trapping monoclonal antibodies (MT-mAbs). The company's proprietary platform engineers antibodies to bind pathogens and tether them to the mucus layer, preventing them from reaching and infecting target cells. This technology is primarily focused on treating and preventing infectious diseases at mucosal surfaces, such as the respiratory and female reproductive tracts. By enhancing the natural barrier function of mucus, Mucora aims to provide a new layer of defense against viruses like HSV and RSV. The company is a spin-out from Johns Hopkins University, leveraging decades of research into mucus and nanoparticle drug delivery.